We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026

Growing European Demand for Mad Cow Test

By HospiMedica staff writers
Posted on 29 Jan 2001
U.S. More...
company Bio-Rad Laboratories (Hercules, CA) has become a leading provider of tests for bovine spongiform encephalopathy (BSE) in Europe. The company reports it has received orders for more than one million enzyme-linked immunosorbent assays (ELISA) for BSE, known as mad cow disease.

Since October 2000, the fear of BSE has spread quickly throughout Europe, as more cattle were found with the disease. Cows with BSE have been discovered in France, Germany, Spain, Portugal, and Italy. On January 1, 2001, the countries of the European Union commenced mandatory testing of all beef livestock over the age of 30 months in order to insure the highest quality and safety of the European food chain. According to media reports, seven million cattle will have to be tested in Europe this year.

Called Platelia, Bio-Rad's test was selected by the European Commission (EC) as one of the three most sensitive BSE tests and is among the three approved in the most recent EC report. Two independent reports commissioned by a directorate of the EC further substantiated Bio-Rad's test as the preferred test for diagnosing BSE in European cattle. The test is in a screening format for use in high throughput environments, providing results in about four hours.

To meet the demand for tests, Bio-Rad has increased manufacturing capabilities at its French facilities and is mobilizing employees around the world to support the scaling up of production. "We have allocated substantial resources to ensure that we can rapidly meet the growing needs for a quick, clear, and accurate test,” said David Schwartz, president and CEO of Bio-Rad.



Related Links:
Bio-Rad

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Thyroid Test
Anti-Thyroid EIA Test
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.